<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:55:09Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10070065" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10070065</identifier>
        <datestamp>2023-04-05</datestamp>
        <setSpec>rheumatology</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="iso-abbrev">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="publisher-id">brheum</journal-id>
              <journal-title-group>
                <journal-title>Rheumatology (Oxford, England)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1462-0324</issn>
              <issn pub-type="epub">1462-0332</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10070065</article-id>
              <article-id pub-id-type="pmcid">PMC10070065</article-id>
              <article-id pub-id-type="pmc-uid">10070065</article-id>
              <article-id pub-id-type="pmid">36018235</article-id>
              <article-id pub-id-type="pmid">36018235</article-id>
              <article-id pub-id-type="doi">10.1093/rheumatology/keac491</article-id>
              <article-id pub-id-type="publisher-id">keac491</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Science</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00360</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a <italic toggle="yes">post hoc</italic> analysis of the TULIP-1 and TULIP-2 trials</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3047-500X</contrib-id>
                  <name>
                    <surname>Bruce</surname>
                    <given-names>Ian N</given-names>
                  </name>
                  <aff><institution>Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre</institution>, Manchester, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>van Vollenhoven</surname>
                    <given-names>Ronald F</given-names>
                  </name>
                  <aff><institution>Amsterdam Rheumatology and Immunology Center, University of Amsterdam</institution>, Amsterdam, <country country="NL">The Netherlands</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9507-3338</contrib-id>
                  <name>
                    <surname>Morand</surname>
                    <given-names>Eric F</given-names>
                  </name>
                  <aff><institution>School of Clinical Sciences at Monash Health, Monash University</institution>, Melbourne, VIC, <country country="AU">Australia</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Furie</surname>
                    <given-names>Richard A</given-names>
                  </name>
                  <aff><institution>Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell</institution>, Great Neck, NY, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Manzi</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <aff><institution>Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network</institution>, Pittsburgh, PA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>White</surname>
                    <given-names>William B</given-names>
                  </name>
                  <aff><institution>Calhoun Cardiology Center, University of Connecticut School of Medicine</institution>, Farmington, CT, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Abreu</surname>
                    <given-names>Gabriel</given-names>
                  </name>
                  <aff><institution>BioPharmaceuticals R&amp;D, AstraZeneca R&amp;D</institution>, Gothenburg, <country country="SE">Sweden</country></aff>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Tummala</surname>
                    <given-names>Raj</given-names>
                  </name>
                  <aff><institution>BioPharmaceuticals R&amp;D, AstraZeneca US</institution>, Gaithersburg, MD, <country country="US">USA</country></aff>
                  <xref rid="keac491-cor1" ref-type="corresp"/>
                  <!--Raj.Tummala@astrazeneca.com-->
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="keac491-cor1">Correspondence to: Raj Tummala, Global Clinical Head, Late Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA. E-mail: <email>Raj.Tummala@astrazeneca.com</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-08-26">
                <day>26</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>26</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <volume>62</volume>
              <issue>4</issue>
              <fpage>1526</fpage>
              <lpage>1534</lpage>
              <history>
                <date date-type="received">
                  <day>31</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>26</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="keac491.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Objectives</title>
                  <p>Glucocorticoid sparing is a key priority for SLE management. We evaluated the effects of sustained glucocorticoid tapering in patients with SLE.</p>
                </sec>
                <sec id="s2">
                  <title>Material and methods</title>
                  <p>This was a <italic toggle="yes">post hoc</italic> analysis of the randomized, placebo-controlled, 52-week phase 3 Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-1 and TULIP-2 trials of anifrolumab (300 mg i.v. once every 4 weeks for 48  weeks) plus standard therapy in patients with moderate to severe SLE. In a cohort of patients receiving glucocorticoids (prednisone or equivalent) 10 mg or more per day at baseline, we assessed changes in glucocorticoid dosage, patient-reported outcomes (PROs) and safety. Outcome measures were compared between sustained glucocorticoid taper responders (7.5 mg or less per day by week 40 sustained through week 52) and non-responders, regardless of treatment group, and between patients receiving anifrolumab or placebo.</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p>Among the 726 patients in the TULIP trials, 375 patients received glucocorticoids 10 mg or more per day at baseline, and of these, 155 (41%) patients were sustained glucocorticoid taper responders. Compared with non-responders (<italic toggle="yes">n</italic> = 220), sustained glucocorticoid taper responders reduced their mean cumulative glucocorticoid dose by 32%, improved PRO scores, reduced blood pressure and experienced fewer serious adverse events. Sustained glucocorticoid tapering was achieved by 51% (96/190) of patients receiving anifrolumab <italic toggle="yes">vs</italic> 32% (59/185) receiving placebo. Compared with placebo, more anifrolumab-treated patients achieved both sustained glucocorticoid taper and reduced overall disease activity [38% (72/190) <italic toggle="yes">vs</italic> 23% (43/185)].</p>
                </sec>
                <sec id="s4">
                  <title>Conclusions</title>
                  <p>Sustained glucocorticoid tapering is associated with clinical benefits. Anifrolumab treatment has potential to reduce disease activity and glucocorticoid exposure, a key goal of SLE management.</p>
                </sec>
                <sec id="s5">
                  <title>Study Registration</title>
                  <p>ClinicalTrials.gov identifier: NCT02446912 and NCT02446899.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <title>Graphical Abstract</title>
                <p>
                  <fig position="float" id="keac491-F4">
                    <label>Graphical Abstract</label>
                    <graphic xlink:href="keac491f4" position="float"/>
                  </fig>
                </p>
              </abstract>
              <kwd-group>
                <kwd>SLE</kwd>
                <kwd>glucocorticoids</kwd>
                <kwd>biologics</kwd>
                <kwd>clinical trials</kwd>
                <kwd>glucocorticoids</kwd>
                <kwd>glucocorticoid sparing</kwd>
                <kwd>patient-reported outcomes</kwd>
                <kwd>cardiovascular</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>AstraZeneca</institution>
                      <institution-id institution-id-type="DOI">10.13039/100004325</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <boxed-text id="keac491-BOX1" position="float">
              <label>Rheumatology key messages</label>
              <list list-type="bullet">
                <list-item>
                  <p>Sustained glucocorticoid tapering is associated with improved patient-reported outcomes and blood pressure, and fewer serious adverse events.</p>
                </list-item>
                <list-item>
                  <p>Treatment with anifrolumab facilitated glucocorticoid tapering while improving overall disease activity in patients with SLE.</p>
                </list-item>
                <list-item>
                  <p>These findings provide evidence to support the clinical benefits of minimizing glucocorticoid exposure.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro">
              <title>Introduction</title>
              <p>SLE is a chronic, multisystem autoimmune disease that runs a relapsing and remitting course [<xref rid="keac491-B1" ref-type="bibr">1</xref>]. Despite current treatments, SLE continues to cause significant morbidity, increased mortality risk and poor health-related quality of life [<xref rid="keac491-B1" ref-type="bibr">1–5</xref>].</p>
              <p>Glucocorticoids are used in up to 80% of patients with SLE; the majority being treated long-term [<xref rid="keac491-B6" ref-type="bibr">6</xref>, <xref rid="keac491-B7" ref-type="bibr">7</xref>]. Despite their short-term benefits, glucocorticoids are associated with a significant burden of toxicity [<xref rid="keac491-B8" ref-type="bibr">8</xref>]. Compared with patients not taking glucocorticoids, patients with SLE taking a mean prednisone dosage above 7.5 mg per day over a 4-year period had a nearly 10-fold increased risk of organ damage, including cataracts, osteoporotic fractures, diabetes mellitus and cardiovascular disease [<xref rid="keac491-B7" ref-type="bibr">7</xref>, <xref rid="keac491-B9" ref-type="bibr">9</xref>, <xref rid="keac491-B10" ref-type="bibr">10</xref>]. By contrast, daily doses of 7.5 mg or less per day are associated with fewer adverse effects [<xref rid="keac491-B7" ref-type="bibr">7</xref>, <xref rid="keac491-B9" ref-type="bibr">9</xref>].</p>
              <p>Anifrolumab is a human mAb that targets type I IFN receptor subunit 1 with high specificity and affinity to reduce signalling by type I IFNs [<xref rid="keac491-B11" ref-type="bibr">11</xref>]. Two phase 3 trials, Treatment of Uncontrolled Lupus via the Interferon Pathway-1 (TULIP-1; NCT02446912) and TULIP-2 (NCT02446899), evaluated the efficacy and safety of anifrolumab in patients with moderate to severe SLE despite standard therapy over 52 weeks [<xref rid="keac491-B12" ref-type="bibr">12</xref>, <xref rid="keac491-B13" ref-type="bibr">13</xref>]. A key secondary endpoint of these trials was oral glucocorticoid (prednisone or equivalent) dosage reduction to 7.5 mg or less per day by week 40 that was sustained to week 52 in patients receiving 10 mg or more per day at baseline. Sustained glucocorticoid taper response rate treatment differences of 17% and 21% between anifrolumab and placebo were observed at week 52 in the TULIP-1 and TULIP-2 trials, respectively [<xref rid="keac491-B12" ref-type="bibr">12</xref>, <xref rid="keac491-B13" ref-type="bibr">13</xref>].</p>
              <p>In a pooled cohort of patients receiving glucocorticoids 10 mg or more per day at baseline from the TULIP trials, irrespective of treatment assignment, we aimed to investigate changes associated with a sustained glucocorticoid taper response with regard to patient-reported outcomes (PROs), serious adverse events (SAEs), cardiovascular AEs and clinical and laboratory values.</p>
            </sec>
            <sec sec-type="methods">
              <title>Patients and methods</title>
              <sec>
                <title>Patients and study design</title>
                <p>Pooled phase 3 data were analysed from the 52-week TULIP-1 and TULIP-2 trials of anifrolumab in patients with moderate to severe SLE, despite standard therapy with glucocorticoids, antimalarials and/or immunosuppressants, randomized to i.v. anifrolumab 300 mg or placebo every 4 weeks for 48 weeks. Study design and methods have been described previously [<xref rid="keac491-B12" ref-type="bibr">12</xref>, <xref rid="keac491-B13" ref-type="bibr">13</xref>]. Briefly, eligible patients were 18–70 years of age and fulfilled the ACR 1997 classification criteria for SLE [<xref rid="keac491-B14" ref-type="bibr">14</xref>]. For patients receiving glucocorticoids (prednisone or equivalent) 10 mg or more per day at baseline, a protocol-mandated attempt to taper to 7.5 mg or less per day was required between weeks 8 and 40. Stable oral glucocorticoid dosage was required between weeks 40 and 52.</p>
              </sec>
              <sec>
                <title>Study endpoints and assessments</title>
                <p>We evaluated the prespecified secondary endpoint of sustained glucocorticoid taper response at week 52 in pooled TULIP data for a cohort of patients receiving baseline glucocorticoids 10 mg or more per day. A sustained glucocorticoid taper response was defined as achieving a glucocorticoid dosage 7.5 mg or less per day by week 40 and sustained through week 52, having no premature discontinuation of investigational product or use of restricted medications beyond the protocol-allowed threshold. Non-responders were defined as patients who could not be evaluated at week 52 (e.g. owing to missing values). Analyses therefore included only patients receiving baseline glucocorticoids 10 mg or more per day randomized to anifrolumab 300 mg or placebo; the anifrolumab 150-mg group in TULIP-1 was excluded. Pooled patient data were evaluated for sustained glucocorticoid taper response, regardless of treatment group assignment. We subsequently assessed several outcomes in this cohort by treatment group.</p>
              </sec>
              <sec>
                <title>Outcomes assessed</title>
                <p>Outcome measures were compared between sustained glucocorticoid taper responders and non-responders at week 52, regardless of treatment group assignment. We compared cumulative dose of glucocorticoids measured by the mean area under the curve (AUC). Changes in PROs were assessed from baseline to week 52, including responses in Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) (defined as &gt;3-point improvement) and 36-Item Short Form Health Survey version 2 (SF-36-v2) (acute) physical component summary (PCS) and mental component summary (MCS) (defined as &gt;3.4 improvement in the PCS and &gt;4.6 improvement in the MCS) [<xref rid="keac491-B15" ref-type="bibr">15</xref>, <xref rid="keac491-B16" ref-type="bibr">16</xref>]. Mean changes were assessed from baseline to week 52 for weight, BMI, fasting glucose, cholesterol, haematologic values (haematocrit, erythrocytes, leukocytes, lymphocytes, neutrophils and platelets), as well as least squares (LS) mean changes in systolic and diastolic blood pressure and pulse rate assessed at week 40 and week 52. SAEs and cardiovascular AEs were also assessed.</p>
              </sec>
              <sec>
                <title>Outcomes assessed in anifrolumab 300 mg and placebo treatment groups</title>
                <p>Outcome measures were compared between patients receiving baseline glucocorticoids 10 mg or more per day randomized to anifrolumab 300 mg or placebo, including the percentage of patients achieving a sustained glucocorticoid taper response, LS mean changes from baseline glucocorticoid daily dose, cumulative dose of glucocorticoids, PRO improvements and safety. The percentage of sustained glucocorticoid taper responders and BILAG-based Composite Lupus Assessment (BICLA) responders, as defined in the TULIP trials, were compared between treatment groups [<xref rid="keac491-B12" ref-type="bibr">12</xref>, <xref rid="keac491-B13" ref-type="bibr">13</xref>].</p>
              </sec>
              <sec>
                <title>Statistical analyses</title>
                <p>Changes from baseline were analysed using a mixed model with repeated measures, responder <italic toggle="yes">vs</italic> non-responder rates were calculated using a stratified Cochran–Mantel–Haenszel approach and glucocorticoid AUC, with an analysis of covariance model. Analyses included stratification factors of treatment group, visit (including study for the pooled analysis), SLE Disease Activity Index 2000 score at screening (&lt;10 points <italic toggle="yes">vs</italic> ≥10 points), type I IFN gene signature test result at screening (high <italic toggle="yes">vs</italic> low) and, when appropriate, the baseline glucocorticoid dosage (&lt;10 mg per day or ≥10 mg per day). All <italic toggle="yes">P</italic>-values, 95% CIs and <sc>s</sc>.<sc>e</sc>. are based on these models. As these analyses were not part of the formal testing strategy, no adjustment for multiple testing has been applied and all <italic toggle="yes">P</italic>-values are nominal. Missing data were imputed using the last observation carried forward for the first visit with missing data; subsequent visits with missing data were not imputed.</p>
              </sec>
              <sec>
                <title>Study approval</title>
                <p>Both TULIP trials were undertaken in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice. As this was a <italic toggle="yes">post hoc</italic> analysis of anonymized data, no ethics committee or institutional review board approvals were required. All such approvals were obtained in the original trials [<xref rid="keac491-B12" ref-type="bibr">12</xref>, <xref rid="keac491-B13" ref-type="bibr">13</xref>].</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Patient demographics and clinical characteristics</title>
                <p>In TULIP-1 and TULIP-2, 726 patients were randomized to anifrolumab 300 mg [<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>360 (180 patients in each trial)] or placebo [<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>366 (184 patients in TULIP-1 and 182 patients in TULIP-2)]. Most patients [595 (82%) of 726] were receiving glucocorticoids at baseline, of whom 375 were receiving glucocorticoids (prednisone or equivalent) 10 mg or more per day (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>190, anifrolumab; <italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>185 placebo) with a mean daily dose of 15.2 mg for both treatment groups. Regardless of treatment group assignment, 155 (41%) of 375 patients achieved a sustained glucocorticoid taper response at week 52. Patient demographics and clinical characteristics were similar between sustained glucocorticoid taper responder and non-responder groups (<xref rid="keac491-T1" ref-type="table">Table 1</xref>).</p>
                <table-wrap position="float" id="keac491-T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Patient demographics and baseline clinical characteristics by sustained glucocorticoid taper response</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="2" align="center" rowspan="1">Patients who received glucocorticoids 10 mg or more per day at baseline (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>375)<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Baseline characteristic</th>
                        <th align="center" rowspan="1" colspan="1">Sustained glucocorticoid taper responders<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref> (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>155)</th>
                        <th align="center" rowspan="1" colspan="1">Sustained glucocorticoid taper non-responders<sup>a</sup> (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>220)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age, mean (<sc>s</sc>.<sc>d</sc>.), years</td>
                        <td rowspan="1" colspan="1">40.2 (11.5)</td>
                        <td rowspan="1" colspan="1">38.7 (11.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">140 (90)</td>
                        <td rowspan="1" colspan="1">202 (92)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">101 (65)</td>
                        <td rowspan="1" colspan="1">146 (66)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black or African American</td>
                        <td rowspan="1" colspan="1">15 (10)</td>
                        <td rowspan="1" colspan="1">31 (14)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">19 (12)</td>
                        <td rowspan="1" colspan="1">19 (9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Other</td>
                        <td rowspan="1" colspan="1">17 (11)</td>
                        <td rowspan="1" colspan="1">20 (9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ethnic group, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Hispanic or Latino</td>
                        <td rowspan="1" colspan="1">40 (26)</td>
                        <td rowspan="1" colspan="1">54 (25)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">IFNGS high at screening, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">134 (87)</td>
                        <td rowspan="1" colspan="1">194 (88)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Time from SLE diagnosis to randomization, median (range), months</td>
                        <td rowspan="1" colspan="1">84 (6–450)</td>
                        <td rowspan="1" colspan="1">88 (4–494)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BILAG-2004</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> At least one A item, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">80 (52)</td>
                        <td rowspan="1" colspan="1">105 (48)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> No A and at least two B items, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">68 (44)</td>
                        <td rowspan="1" colspan="1">95 (43)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> No A and less than two B items, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">7 (5)</td>
                        <td rowspan="1" colspan="1">20 (9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">SLEDAI-2K score, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">11.2 (3.2)</td>
                        <td rowspan="1" colspan="1">12.2 (4.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &lt;10, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">44 (28)</td>
                        <td rowspan="1" colspan="1">53 (24)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≥10, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">111 (72)</td>
                        <td rowspan="1" colspan="1">167 (76)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">PGA score, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">1.8 (0.4)</td>
                        <td rowspan="1" colspan="1">1.9 (0.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CLASI activity score, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">9.5 (7.7)</td>
                        <td rowspan="1" colspan="1">8.4 (7.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &lt;10, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">94 (61)</td>
                        <td rowspan="1" colspan="1">153 (70)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≥10, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">61 (40)</td>
                        <td rowspan="1" colspan="1">67 (30)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 0, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">8 (5)</td>
                        <td rowspan="1" colspan="1">11 (5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &gt;0, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">147 (95)</td>
                        <td rowspan="1" colspan="1">209 (95)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">SDI global score, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">0.5 (0.9)</td>
                        <td rowspan="1" colspan="1">0.6 (0.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Swollen joint count, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">6.1 (4.9)</td>
                        <td rowspan="1" colspan="1">7.3 (6.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Tender joint count, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">10.3 (7.3)</td>
                        <td rowspan="1" colspan="1">10.4 (7.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Oral glucocorticoid use<xref rid="tblfn2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean (<sc>s</sc>.<sc>d</sc>.), mg/day</td>
                        <td rowspan="1" colspan="1">13.5 (5.9)</td>
                        <td rowspan="1" colspan="1">16.4 (10.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Oral glucocorticoid ≥10 mg/day, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">155 (100)</td>
                        <td rowspan="1" colspan="1">220 (100)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Oral glucocorticoid only, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">29 (19)</td>
                        <td rowspan="1" colspan="1">41 (19)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Oral glucocorticoid only, mean (<sc>s</sc>.<sc>d</sc>.), mg/day</td>
                        <td rowspan="1" colspan="1">12.5 (4.5)</td>
                        <td rowspan="1" colspan="1">15.9 (6.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Oral glucocorticoid with antimalarials and/or immunosuppressants, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">126 (81)</td>
                        <td rowspan="1" colspan="1">179 (81)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean (<sc>s</sc>.<sc>d</sc>.), mg/day</td>
                        <td rowspan="1" colspan="1">13.7 (6.1)</td>
                        <td rowspan="1" colspan="1">16.5 (11.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Time on glucocorticoid up to randomization, median (range), months</td>
                        <td rowspan="1" colspan="1">5 (0–198)</td>
                        <td rowspan="1" colspan="1">5 (0–398)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Vital signs, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Systolic, sitting blood pressure, mm Hg</td>
                        <td rowspan="1" colspan="1">119.3 (12.8)</td>
                        <td rowspan="1" colspan="1">118.8 (13.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Diastolic, sitting blood pressure, mm Hg</td>
                        <td rowspan="1" colspan="1">75.2 (9.2)</td>
                        <td rowspan="1" colspan="1">74.2 (9.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Pulse rate, beats/min</td>
                        <td rowspan="1" colspan="1">74.2 (11.0)</td>
                        <td rowspan="1" colspan="1">76.6 (11.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Laboratory parameters, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Weight, kg</td>
                        <td rowspan="1" colspan="1">69.7 (16.8)</td>
                        <td rowspan="1" colspan="1">72.2 (18.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> BMI, kg/m<sup>2</sup></td>
                        <td rowspan="1" colspan="1">26.6 (5.9)</td>
                        <td rowspan="1" colspan="1">26.9 (6.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Fasting glucose, mmol/l</td>
                        <td rowspan="1" colspan="1">4.9 (1.0)</td>
                        <td rowspan="1" colspan="1">4.8 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Total cholesterol, mmol/l</td>
                        <td rowspan="1" colspan="1">5.0 (1.1)</td>
                        <td rowspan="1" colspan="1">5.0 (1.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> HDL, mmol/l</td>
                        <td rowspan="1" colspan="1">1.5 (0.5)</td>
                        <td rowspan="1" colspan="1">1.5 (0.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> LDL, mmol/l</td>
                        <td rowspan="1" colspan="1">2.7 (0.9)</td>
                        <td rowspan="1" colspan="1">2.8 (0.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Triglycerides, mmol/l</td>
                        <td rowspan="1" colspan="1">1.5 (0.8)</td>
                        <td rowspan="1" colspan="1">1.6 (0.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Haematocrit</td>
                        <td rowspan="1" colspan="1">0.4 (0.0)</td>
                        <td rowspan="1" colspan="1">0.4 (0.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Erythrocytes, 10<sup>12</sup>/l</td>
                        <td rowspan="1" colspan="1">4.3 (0.5)</td>
                        <td rowspan="1" colspan="1">4.2 (0.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Leukocytes, 10<sup>9</sup>/l</td>
                        <td rowspan="1" colspan="1">5.7 (2.3)</td>
                        <td rowspan="1" colspan="1">6.2 (2.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Lymphocytes, 10<sup>9</sup>/l</td>
                        <td rowspan="1" colspan="1">1.3 (0.7)</td>
                        <td rowspan="1" colspan="1">1.3 (0.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Neutrophils, 10<sup>9</sup>/l</td>
                        <td rowspan="1" colspan="1">4.0 (1.9)</td>
                        <td rowspan="1" colspan="1">4.5 (2.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Platelets, 10<sup>9</sup>/l</td>
                        <td rowspan="1" colspan="1">242.2 (79.4)</td>
                        <td rowspan="1" colspan="1">254.7 (86.1)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <label>a</label>
                      <p>Sustained glucocorticoid taper responder defined as a glucocorticoid dosage reduction to 7.5 mg or less per day by week 40 without a dosage increase between week 40 and week 52 in patients with a baseline glucocorticoid dosage 10 mg or more per day.</p>
                    </fn>
                    <fn id="tblfn2">
                      <label>b</label>
                      <p>Oral glucocorticoid includes prednisone or equivalent. CLASI: Cutaneous Lupus Erythematosus Disease Area and Severity Index; HDL: high-density lipoprotein; IFNGS: interferon gene signature; LDL: low-density lipoprotein; PGA: Physician’s Global Assessment; SDI: Systemic Lupus International Collaborating Clinics/ACR Damage Index; SLEDAI-2K: SLE Disease Activity Index 2000.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Outcomes for sustained glucocorticoid taper responders <italic toggle="yes">vs</italic> non-responders</title>
                <p>The LS mean cumulative dose of glucocorticoids during the 52 weeks of treatment was 32% lower among patients who were glucocorticoid taper responders <italic toggle="yes">vs</italic> non-responders [LS mean (<sc>s</sc>.<sc>e</sc>.) AUC at week 52: 3172.9 (156.6) mg <italic toggle="yes">vs</italic> 4662.6 (142.6) mg; <italic toggle="yes">P</italic> &lt; 0.001] (<xref rid="sup1" ref-type="supplementary-material">supplementary Fig. S1</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <p>The sustained glucocorticoid taper responder group had more patients with clinically meaningful improvements in FACIT-F, SF-36 PCS and SF-36 MCS scores (all <italic toggle="yes">P</italic> &lt; 0.001) compared with non-responders (<xref rid="keac491-F1" ref-type="fig">Fig. 1</xref>).</p>
                <fig position="float" id="keac491-F1">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Improvement in PROs at week 52 by sustained glucocorticoid taper response.Patients with response in (<bold>A</bold>) FACIT-F, defined as an improvement from baseline &gt;3; (<bold>B</bold>) SF-36 PCS, defined as an increase from baseline &gt;3.4; and (<bold>C</bold>) SF-36 MCS, defined as an increase from baseline &gt;4.6. (A–C) Error bars represent 95% CI. Response rates, 95% CIs, and nominal <italic toggle="yes">P</italic>-values were calculated using a stratified Cochran–Mantel–Haenszel approach. FACIT-F: Functional Assessment of Chronic Illness Therapy–Fatigue; MCS: mental component summary; PCS: physical component summary; PRO: patient-reported outcome; SF-36: 36-Item Short Form Health Survey</p>
                  </caption>
                  <graphic xlink:href="keac491f1" position="float"/>
                </fig>
                <p>Over the 52-week trials, the percentage of patients with one or more AEs was 90% (140 of 155) of sustained glucocorticoid taper responders and 83% (183 of 220) of non-responders. SAE incidence was 17% (26 of 155) in sustained glucocorticoid taper responders and 28% (62 of 220) in non-responders (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S1</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Of SAEs, serious infections, including pneumonia, were most commonly reported, occurring in 9 (6%) of 155 glucocorticoid taper responders and 29 (13%) of 220 non-responders, and worsening of SLE was reported in 4 (3%) of 155 glucocorticoid taper responders and 11 (5%) of 220 non-responders (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S1</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Cardiovascular AEs were reported in 19 (12%) of 155 and 25 (11%) of 220 glucocorticoid taper responders and non-responders, respectively (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S2</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Hypertension was the most common cardiovascular AE reported in both responders and non-responders.</p>
                <p>At week 40, from when glucocorticoid dosage was required to be stable, sustained glucocorticoid taper responders had lower systolic and diastolic sitting blood pressure compared with non-responders (<italic toggle="yes">P</italic> = 0.023 and <italic toggle="yes">P</italic> &lt; 0.001, respectively); differences in diastolic (<italic toggle="yes">P</italic> = 0.010) but not systolic (<italic toggle="yes">P</italic> = 0.38) sitting blood pressure were maintained at week 52 (<xref rid="keac491-T2" ref-type="table">Table 2</xref>). In addition, fewer sustained glucocorticoid taper responders than non-responders started new supplementary blood pressure medications [11 (7%) of 155 <italic toggle="yes">vs</italic> 35 (16%) of 220; <italic toggle="yes">P</italic> = 0.029].</p>
                <table-wrap position="float" id="keac491-T2">
                  <label>Table 2.</label>
                  <caption>
                    <p>Change in blood pressure and pulse rate by sustained glucocorticoid taper response</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="2" align="center" rowspan="1">Patients who received glucocorticoids 10 mg or more per day (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>375)<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Sustained glucocorticoid taper responders (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>155)</th>
                        <th align="center" rowspan="1" colspan="1">Sustained glucocorticoid taper non-responders (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>220)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="3" rowspan="1">Systolic, sitting blood pressure, mm Hg</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Baseline, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">119.3 (12.8)</td>
                        <td rowspan="1" colspan="1">118.8 (13.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 40, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">–2.3 (1.2)</td>
                        <td rowspan="1" colspan="1">0.9 (1.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–3.2 (–5.9, –0.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.023</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 52, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">–0.1 (1.2)</td>
                        <td rowspan="1" colspan="1">1.2 (1.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–1.3 (–4.1, 1.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.38</td>
                      </tr>
                      <tr>
                        <td colspan="3" rowspan="1">Diastolic, sitting blood pressure, mm Hg</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Baseline, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">75.2 (9.2)</td>
                        <td rowspan="1" colspan="1">74.2 (9.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 40, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">–2.4 (0.8)</td>
                        <td rowspan="1" colspan="1">1.0 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–3.4 (–5.3, –1.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-value</italic></td>
                        <td colspan="2" align="center" rowspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 52, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">–1.2 (0.8)</td>
                        <td rowspan="1" colspan="1">1.6 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–2.7 (–4.8, –0.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-value</italic></td>
                        <td colspan="2" align="center" rowspan="1">0.010</td>
                      </tr>
                      <tr>
                        <td colspan="3" rowspan="1">Pulse rate, beats/min</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Baseline, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">74.2 (11.0)</td>
                        <td rowspan="1" colspan="1">76.6 (11.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 40, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">–1.1 (0.8)</td>
                        <td rowspan="1" colspan="1">0.7 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–1.8 (–3.8, 0.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.080</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 52, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">–1.6 (0.8)</td>
                        <td rowspan="1" colspan="1">–1.1 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–0.5 (–2.5, 1.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.62</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn3">
                      <p>LS: least squares.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>At week 52, mean changes in weight, BMI, fasting glucose, cholesterol and laboratory haematological values were generally similar between glucocorticoid responders and non-responders (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S3</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Both groups had moderate increases in weight and BMI from baseline to week 52.</p>
              </sec>
              <sec>
                <title>Outcomes for anifrolumab <italic toggle="yes">vs</italic> placebo groups</title>
                <p>Patient demographics and baseline clinical characteristics were comparable between treatment groups in patients receiving baseline glucocorticoids 10 mg or more per day from the pooled cohort (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S4</xref>, available at <italic toggle="yes">Rheumatology</italic> online). More patients receiving anifrolumab compared with placebo achieved a sustained glucocorticoid taper response [96 (51%) of 190 <italic toggle="yes">vs</italic> 59 (32%) of 185; difference 18.7% (8.9–28.4); <italic toggle="yes">P</italic> &lt; 0.001]. This was also seen when a more stringent threshold of glucocorticoid taper to 5 mg or less per day was applied [61 (32%) of 190 <italic toggle="yes">vs</italic> 35 (19%) of 185; difference 13.4% (4.5–22.2); <italic toggle="yes">P</italic> = 0.003].</p>
                <p>In this population who entered the trials on glucocorticoids 10 mg or more per day, the LS mean cumulative dose of glucocorticoids during the 52 weeks of treatment was 8% lower in the anifrolumab group <italic toggle="yes">vs</italic> the placebo group [LS mean (<sc>s</sc>.<sc>e</sc>.) AUC at week 52: 3876.3 (163.7) mg <italic toggle="yes">vs</italic> 4196.7 (163.3) mg; <italic toggle="yes">P</italic> = 0.066] (<xref rid="sup1" ref-type="supplementary-material">supplementary Fig. S2</xref>, available at <italic toggle="yes">Rheumatology</italic> online). The LS mean (<sc>s</sc>.<sc>e</sc>.) percentage reduction from baseline at week 52 in the daily glucocorticoid dosage was –42.5% (4.5) among patients in the anifrolumab group compared with –27.7% (4.7) among those in the placebo group [LS mean difference –14.8% (–27.17 to –2.42); <italic toggle="yes">P</italic> = 0.021]. More patients in the anifrolumab group than in the placebo group also had more stringent sustained glucocorticoid dosage reduction from baseline between week 40 and week 52, including sustained glucocorticoid reductions of at least 25% (<italic toggle="yes">P</italic> &lt; 0.001), 50% (<italic toggle="yes">P</italic> = 0.001), 75% (<italic toggle="yes">P</italic> = 0.057) and 90% (<italic toggle="yes">P</italic> = 0.086) (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S5</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <p>A total of 89 (47%) of 190 anifrolumab-treated patients who received baseline glucocorticoids ≥10 mg per day achieved a BICLA response at week 52 <italic toggle="yes">vs</italic> 58 (32%) of 185 patients who received placebo (<xref rid="keac491-F2" ref-type="fig">Fig. 2</xref>). In BICLA responders, a high proportion of anifrolumab-treated patients also achieved a sustained glucocorticoid taper response [72 (81%) of 89 who received anifrolumab <italic toggle="yes">vs</italic> 43 (74%) of 58 who received placebo]. Thus, with anifrolumab treatment, 72 (38%) of 190 patients achieved the combination of BICLA response and sustained glucocorticoid taper response at week 52 compared with 43 (23%) of 185 patients who received placebo [difference 14.6% (5.3–23.9); <italic toggle="yes">P</italic> = 0.002] (<xref rid="keac491-F2" ref-type="fig">Fig. 2</xref>).</p>
                <fig position="float" id="keac491-F2">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Sustained glucocorticoid taper response in patients categorized by BICLA response. Response rates were calculated using a stratified Cochran–Mantel–Haenszel approach. BICLA, BILAG-based Composite Lupus Assessment</p>
                  </caption>
                  <graphic xlink:href="keac491f2" position="float"/>
                </fig>
                <p>Anifrolumab treatment, compared with placebo, resulted in more patients with significant improvement in SF-36 MCS scores (<italic toggle="yes">P</italic> = 0.029), but not SF-36 PCS or FACIT-F, regardless of glucocorticoid taper response (<xref rid="keac491-F3" ref-type="fig">Fig. 3</xref>).</p>
                <fig position="float" id="keac491-F3">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Improvement in PROs at week 52 by treatment group. Patients with response in (<bold>A</bold>) FACIT-F, defined as an improvement from baseline &gt;3; (<bold>B</bold>) SF-36 PCS, defined as an increase from baseline &gt;3.4; and (<bold>C</bold>) SF-36 MCS, defined as an increase from baseline &gt;4.6. (A–C) Error bars represent 95% CI. Response rates, 95% CIs and nominal <italic toggle="yes">P</italic>-values were calculated using a stratified Cochran–Mantel–Haenszel approach. FACIT-F: Functional Assessment of Chronic Illness Therapy–Fatigue; MCS: mental component summary; PCS: physical component summary; PRO: patient-reported outcome; SF-36: 36-Item Short Form Health Survey</p>
                  </caption>
                  <graphic xlink:href="keac491f3" position="float"/>
                </fig>
                <p>The incidence of SAEs was 21% (40 of 190) in the anifrolumab group and 26% (48 of 185) in the placebo group (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S6</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Of SAEs, worsening of SLE occurred in 4 (2%) of 190 patients who received anifrolumab and 11 (6%) of 185 who received placebo. Cardiovascular AEs were reported in 10% (19 of 190) and 14% (25 of 185) of patients in the anifrolumab and placebo groups, respectively (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S7</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Of cardiovascular AEs, hypertension occurred in 4 (2%) of 190 patients who received anifrolumab and 11 (6%) of 185 who received placebo.</p>
                <p>Systolic and diastolic blood pressure and pulse rate were lower at week 40 with anifrolumab treatment compared with placebo (0.022 and 0.033, respectively; <italic toggle="yes">P</italic> = 0.017); at week 52, between-group treatment differences were not significantly different (<xref rid="keac491-T3" ref-type="table">Table 3</xref>). The use of supplementary antihypertensive medications started during treatment was lower in the anifrolumab group than in the placebo group [12 (6%) of 190 <italic toggle="yes">vs</italic> 34 (18%) of 185; <italic toggle="yes">P</italic> = 0.001].</p>
                <table-wrap position="float" id="keac491-T3">
                  <label>Table 3.</label>
                  <caption>
                    <p>Change in blood pressure and pulse rate by treatment group</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                      <col valign="top" align="char" char="(" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="2" align="center" rowspan="1">Patients who received glucocorticoids 10 mg or more per day at baseline (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>375)<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Placebo (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>185)</th>
                        <th align="center" rowspan="1" colspan="1">Anifrolumab 300 mg (<italic toggle="yes">n </italic>=<italic toggle="yes"> </italic>190)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="3" rowspan="1">Systolic, sitting blood pressure, mm Hg</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Baseline, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">119.3 (13.8)</td>
                        <td rowspan="1" colspan="1">118.7 (13.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 40, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">1.2 (1.1)</td>
                        <td rowspan="1" colspan="1">–2.2 (1.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–3.3 (–6.1, –0.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.017</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 52, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">1.5 (1.2)</td>
                        <td rowspan="1" colspan="1">–0.2 (1.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–1.6 (–4.5, 1.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.26</td>
                      </tr>
                      <tr>
                        <td colspan="3" rowspan="1">Diastolic, sitting blood pressure, mm Hg</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Baseline, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">74.7 (9.6)</td>
                        <td rowspan="1" colspan="1">74.6 (8.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 40, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">0.5 (0.8)</td>
                        <td rowspan="1" colspan="1">–1.7 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–2.2 (–4.1, –0.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.022</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 52, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">0.9 (0.8)</td>
                        <td rowspan="1" colspan="1">–0.5 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–1.4 (–3.4, 0.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.20</td>
                      </tr>
                      <tr>
                        <td colspan="3" rowspan="1">Pulse rate, beats/min</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Baseline, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">75.5 (10.9)</td>
                        <td rowspan="1" colspan="1">75.7 (11.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 40, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">1.0 (0.8)</td>
                        <td rowspan="1" colspan="1">–1.2 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–2.2 (–4.1, –0.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.033</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Week 52, change from baseline, LS mean (<sc>s</sc>.<sc>e</sc>.)</td>
                        <td rowspan="1" colspan="1">–0.5 (0.8)</td>
                        <td rowspan="1" colspan="1">–2.2 (0.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Difference, LS mean (95% CI)</td>
                        <td colspan="2" align="center" rowspan="1">–1.7 (–3.6, 0.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Nominal <italic toggle="yes">P-</italic>value</td>
                        <td colspan="2" align="center" rowspan="1">0.092</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn4">
                      <p>LS: least squares.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Mean changes in weight, BMI, fasting glucose and cholesterol at week 52 were generally similar between treatment groups (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S8</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Both groups experienced increases in weight and BMI from baseline at week 52. Anifrolumab treatment also resulted in increases in most haematological laboratory values (erythrocytes, leukocytes, lymphocytes, neutrophils and platelets); in contrast, there were stable or small reductions in these laboratory values in the placebo group (<xref rid="sup1" ref-type="supplementary-material">supplementary Table S8</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>Controlling disease activity and avoiding drug toxicity from glucocorticoid use are two of the most important treatment goals highlighted in SLE disease management guidelines [<xref rid="keac491-B17" ref-type="bibr">17</xref>]. The primary aim of this study was to investigate clinically meaningful changes associated with sustained glucocorticoid taper and the associated impact of sustained glucocorticoid reduction on PROs. In our analysis of pooled data from the TULIP trials of anifrolumab in patients with moderate to severe SLE receiving standard therapy, we assessed the downstream effects of a sustained glucocorticoid taper regardless of original treatment assignment. Sustained glucocorticoid tapering was associated with a 32% reduction in the LS mean cumulative glucocorticoid dose used over 52 weeks. Patients with sustained glucocorticoid tapering were more likely to have meaningful improvements in fatigue, physical and mental health and reduced blood pressures compared with glucocorticoid non-responders. A sustained taper was also associated with numerically fewer SAEs, including infections. Anifrolumab treatment facilitated more glucocorticoid tapering compared with placebo, and anifrolumab-treated patients were more likely to achieve the combination of sustained glucocorticoid taper and reduced disease activity, as assessed by BICLA.</p>
              <p>In SLE, persistent disease activity and higher glucocorticoid use are major predictors of organ damage [<xref rid="keac491-B2" ref-type="bibr">2</xref>, <xref rid="keac491-B18" ref-type="bibr">18</xref>, <xref rid="keac491-B19" ref-type="bibr">19</xref>]. Thus, controlling disease activity with the lowest glucocorticoid dosage achievable is an important treatment goal for both clinicians and patients [<xref rid="keac491-B17" ref-type="bibr">17</xref>]. Complete steroid-free clinical remission is difficult to achieve in the real world, particularly in those receiving prolonged glucocorticoid therapy [<xref rid="keac491-B18" ref-type="bibr">18</xref>]. Nevertheless, reducing glucocorticoid exposure is beneficial and has been reported to limit the negative effects of glucocorticoids regardless of whether the patient reaches a low dosage (7.5 mg or less per day) [<xref rid="keac491-B2" ref-type="bibr">2</xref>, <xref rid="keac491-B7" ref-type="bibr">7</xref>], as each 1 mg per day reduction in mean prednisone dosage is associated with an estimated 3–6% reduction in future organ damage risk [<xref rid="keac491-B6" ref-type="bibr">6</xref>, <xref rid="keac491-B20" ref-type="bibr">20</xref>]. In the present study, a sustained glucocorticoid taper was associated with improvements in PROs, including less fatigue and improved physical and mental health. The mechanisms behind these improvements may, in part, be directly related to reduced glucocorticoid dosage as sleep disturbance, mood disorders and catabolic effects on muscle are recognized adverse effects of higher glucocorticoid dosages [<xref rid="keac491-B9" ref-type="bibr">9</xref>].</p>
              <p>The risk of coronary heart disease is increased in SLE [<xref rid="keac491-B21" ref-type="bibr">21</xref>, <xref rid="keac491-B22" ref-type="bibr">22</xref>]. Glucocorticoid use is a likely risk factor, independent of SLE disease activity [<xref rid="keac491-B23" ref-type="bibr">23</xref>]. Higher glucocorticoid doses are also associated with exacerbation of known cardiovascular risk factors including increases in total cholesterol, blood pressure, blood glucose, triglycerides and body weight [<xref rid="keac491-B24" ref-type="bibr">24–26</xref>]. We found that glucocorticoid tapering was associated with reductions in systolic and diastolic blood pressure at week 40 when glucocorticoid dosage was required to be stable. Studies have shown that even numerically small reductions in blood pressure can contribute to clinically relevant reduction in long-term risk of future cardiovascular disease. Both epidemiologic studies and clinical trials have demonstrated association between reduction in blood pressure and corresponding risk of cardiac events. An early analysis of data from the Framingham Heart Study reported that a 2 mm Hg reduction in diastolic blood pressure resulted in a 6% reduction in the risk of coronary heart disease and a 15% reduction in the risk of stroke and transient ischaemic attack [<xref rid="keac491-B27" ref-type="bibr">27</xref>]. The more recent US-based Atherosclerosis Risk in Communities study, including over 15 000 participants, found that a population-wide reduction in systolic blood pressure of 1 or 2 mm Hg was associated with reductions in coronary heart disease, stroke and heart failure [<xref rid="keac491-B28" ref-type="bibr">28</xref>]. Additionally, a systematic review of 86 trials revealed that a reduction in blood pressure of 6/3 mm Hg reduced the risk of stroke by 18% and coronary heart disease by 14% [<xref rid="keac491-B29" ref-type="bibr">29</xref>].</p>
              <p>Of note, fewer patients who tapered glucocorticoids started a new antihypertensive medication during the trial; this is a surrogate measure for better overall blood pressure control, due in part to the glucocorticoid tapering observed in this group. Higher rates of non-responders initiating new prescription antihypertensives during the study would have resulted in a lowering of blood pressure in this group, which may explain the similar observed mean change in blood pressure in both groups by week 52. Since adding an antihypertensive would tend to minimize the absolute differences in observed blood pressure, we feel lower blood pressure is a real benefit of glucocorticoid tapering in this population.</p>
              <p>Of interest, mean changes in weight and BMI showed modest increases in both sustained glucocorticoid taper responders and non-responders. Weight gain in non-responders may reflect ongoing use of high glucocorticoid dosages [<xref rid="keac491-B25" ref-type="bibr">25</xref>, <xref rid="keac491-B30" ref-type="bibr">30</xref>, <xref rid="keac491-B31" ref-type="bibr">31</xref>]. In contrast, weight gain in responders, who are more likely to have also achieved a BICLA response, may reflect overall improved health status. As physical function improves, patients may increase exercise over time and changes in body composition will also need to be factored in to fully understand the impact of this observation. A recent small study did not show associations of glucocorticoid use with metabolic syndrome in SLE [<xref rid="keac491-B32" ref-type="bibr">32</xref>], suggesting the biology of glucocorticoid-induced physiological changes may be modified by the SLE disease process. This hypothesis was supported by a study showing substantial effects of type I IFN on glucocorticoid-regulated genes in SLE [<xref rid="keac491-B33" ref-type="bibr">33</xref>].</p>
              <p>We observed a clinically meaningful effect of tapering glucocorticoids on fatigue, as well as physical and mental health. More patients who were able to taper glucocorticoids improved FACIT-F and SF-36 PCS and MCS scores above minimal clinically important differences (MCIDs) than patients who were unable to taper glucocorticoids. The MCIDs used in this analysis correspond to the MCIDs specified for the TULIP trials, which were derived from the general population. The threshold for response was higher for SF-36 MCS and PCS in our analysis than in a separate analysis of PROs in the TULIP trials, which used MCIDs for SF-36 derived from patients with SLE [<xref rid="keac491-B34" ref-type="bibr">34</xref>]. Even with the higher response threshold for SF-36 PCS (3.4 <italic toggle="yes">vs</italic> 2.5) and MCS (4.6 <italic toggle="yes">vs</italic> 2.5), significant effects were observed in glucocorticoid taper responders. These data suggest that reducing glucocorticoid use has a positive impact on key outcomes from the patients’ perspective.</p>
              <p>More anifrolumab-treated patients were able to taper glucocorticoids to 7.5 mg or less per day and had lower cumulative glucocorticoid use <italic toggle="yes">vs</italic> placebo over the 52-week TULIP trials. Several benefits on health-related quality of life and glucocorticoid adverse effects demonstrated for sustained glucocorticoid taper responders were also observed in the anifrolumab-treated patients compared with the placebo group. Although the differences between treatment groups were generally smaller than for the glucocorticoid taper responder group, possibly due to restricting the analysis to the pool of patients receiving baseline glucocorticoids 10 mg or more per day, anifrolumab-treated patients had meaningful improvements in mental health (SF-36 MCS), improved blood pressure and fewer AEs. Almost twice as many anifrolumab-treated patients had combined reduced disease activity as measured by BICLA and sustained glucocorticoid taper compared with placebo.</p>
              <p>We acknowledge several limitations in our analysis. While data were collected prospectively, the pooled data used were not part of the general testing strategy. In addition, the glucocorticoid responder group was compared based on post-randomization characteristics, which may have resulted in imbalances of baseline characteristics and stratification factors. The TULIP trials were not designed to demonstrate clinical efficacy in blood pressure and other glucocorticoid-associated and although we observed improvements in blood pressure values, future studies are necessary to determine the clinical relevance of glucocorticoid-associated changes in SLE patients. Furthermore, a 52-week trial duration may be too short to examine the full benefits of lower glucocorticoid use. We also have no data on other important glucocorticoid-mediated effects such as bone mineral density and body composition. A long-term extension study is underway that will further assess the long-term benefits of improved disease control and lower glucocorticoid therapy use in this population.</p>
              <p>In conclusion, our pooled analysis of the TULIP trials demonstrated that sustained glucocorticoid tapering was associated with several key benefits in patients with moderate to severe SLE, including improved health status, numerically fewer SAEs and improvements in blood pressure control. These data confirm the importance of minimizing glucocorticoid use as a key treatment goal in SLE management. We also found that anifrolumab treatment enabled sustained glucocorticoid tapering, while improving overall SLE disease activity, which supports its potential to achieve this key goal in patients with SLE.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>keac491_Supplementary_Data</label>
                <media xlink:href="keac491_supplementary_data.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="ack1">
              <title>Acknowledgements</title>
              <p>The authors would like to thank the investigators, research staff, healthcare providers, patients and caregivers who contributed to this study. I.N.B. is a National Institute for Health Research (NIHR) Senior Investigator Emeritus and is funded by the NIHR Manchester Biomedical Research Centre. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Medical writing support was provided by Rebecca S. Jones, PhD, of JK Associates Inc., part of Fishawack Health. This support was funded by AstraZeneca. The academic authors did not receive remuneration for authorship.</p>
            </ack>
            <sec>
              <title>Supplementary data</title>
              <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Rheumatology</italic> online.</p>
            </sec>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at <ext-link xlink:href="https://https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure" ext-link-type="uri">https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ext-link>.</p>
            </sec>
            <sec>
              <title>Funding</title>
              <p>This work was supported by AstraZeneca.</p>
              <p><italic toggle="yes">Disclosure statement</italic>: I.N.B. has received grant or research support from Genzyme/Sanofi and GSK; received consulting and speaking fees from AstraZeneca, BMS and UCB; received consulting and honoraria from GSK; and received consulting fees from Aurinia, Lilly, IL-TOO and Merck Serono. R.F.v.V. has received grant or research support from BMS, GSK, Lilly and UCB; received consulting fees from AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier and UCB; and received honoraria from AbbVie, AstraZeneca, Galapagos, Janssen, Pfizer and UCB. E.F.M. has received grant support from, was a consultant for and was a speaker at a speaker bureau for AstraZeneca; received grant support and consulting fees from AbbVie, BMS, Lilly, GSK, Janssen, Merck Serono and UCB; received grant support from BMS; and received consulting fees from Amgen, Biogen, CSL Inc., Neovacs and Wolf Biotherapeutics. R.A.F. and S.M. have received grant or research support and consulting fees from AstraZeneca. W.B.W. is chair of the cardiovascular safety committee for the TULIP trials and received consulting fees for that work. G.A. is an employee of AstraZeneca. R.T. is a shareholder and employee of AstraZeneca.</p>
            </sec>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="keac491-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaul</surname><given-names>A</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>C</given-names></string-name>, <string-name><surname>Crow</surname><given-names>MK</given-names></string-name></person-group><etal>et al</etal><article-title>Systemic lupus erythematosus</article-title>. <source>Nat Rev Dis Primers</source><year>2016</year>;<volume>2</volume>:<fpage>16039</fpage>.<pub-id pub-id-type="pmid">27306639</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bruce</surname><given-names>IN</given-names></string-name>, <string-name><surname>O'Keeffe</surname><given-names>AG</given-names></string-name>, <string-name><surname>Farewell</surname><given-names>V</given-names></string-name></person-group><etal>et al</etal><article-title>Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort</article-title>. <source>Ann Rheum Dis</source><year>2015</year>;<volume>74</volume>:<fpage>1706</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">24834926</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Drenkard</surname><given-names>C</given-names></string-name>, <string-name><surname>Bao</surname><given-names>G</given-names></string-name>, <string-name><surname>Dennis</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States</article-title>. <source>Arthritis Care Res (Hoboken)</source><year>2014</year>;<volume>66</volume>:<fpage>878</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">24339382</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holloway</surname><given-names>L</given-names></string-name>, <string-name><surname>Humphrey</surname><given-names>L</given-names></string-name>, <string-name><surname>Heron</surname><given-names>L</given-names></string-name></person-group><etal>et al</etal><article-title>Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance</article-title>. <source>Health Qual Life Outcomes</source><year>2014</year>;<volume>12</volume>:<fpage>116</fpage>.<pub-id pub-id-type="pmid">25048687</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jorge</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lu</surname><given-names>N</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Rai</surname><given-names>SK</given-names></string-name>, <string-name><surname>Choi</surname><given-names>HK.</given-names></string-name></person-group><article-title>Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999–2014)</article-title>. <source>Rheumatology (Oxford)</source><year>2018</year>;<volume>57</volume>:<fpage>337</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">29121273</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Apostolopoulos</surname><given-names>D</given-names></string-name>, <string-name><surname>Kandane-Rathnayake</surname><given-names>R</given-names></string-name>, <string-name><surname>Louthrenoo</surname><given-names>W</given-names></string-name></person-group><etal>et al</etal><article-title>Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study</article-title>. <source>Lancet Rheumatol</source><year>2020</year>;<volume>2</volume>:<fpage>e24</fpage>–<lpage>30</lpage>.</mixed-citation>
              </ref>
              <ref id="keac491-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ruiz-Arruza</surname><given-names>I</given-names></string-name>, <string-name><surname>Ugarte</surname><given-names>A</given-names></string-name>, <string-name><surname>Cabezas-Rodriguez</surname><given-names>I</given-names></string-name></person-group><etal>et al</etal><article-title>Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source><year>2014</year>;<volume>53</volume>:<fpage>1470</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">24681836</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lateef</surname><given-names>A</given-names></string-name>, <string-name><surname>Petri</surname><given-names>M.</given-names></string-name></person-group><article-title>Unmet medical needs in systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source><year>2012</year>;<volume>14</volume>:<fpage>S4</fpage>.<pub-id pub-id-type="pmid">23281889</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></string-name>, <string-name><surname>Danza</surname><given-names>A</given-names></string-name>, <string-name><surname>Khamashta</surname><given-names>M.</given-names></string-name></person-group><article-title>Glucocorticoid use and abuse in SLE</article-title>. <source>Rheumatology (Oxford)</source><year>2012</year>;<volume>51</volume>:<fpage>1145</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">22271756</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zonana-Nacach</surname><given-names>A</given-names></string-name>, <string-name><surname>Barr</surname><given-names>SG</given-names></string-name>, <string-name><surname>Magder</surname><given-names>LS</given-names></string-name>, <string-name><surname>Petri</surname><given-names>M.</given-names></string-name></person-group><article-title>Damage in systemic lupus erythematosus and its association with corticosteroids</article-title>. <source>Arthritis Rheum</source><year>2000</year>;<volume>43</volume>:<fpage>1801</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">10943870</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peng</surname><given-names>L</given-names></string-name>, <string-name><surname>Oganesyan</surname><given-names>V</given-names></string-name>, <string-name><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name><surname>Dall’Acqua</surname><given-names>WF</given-names></string-name>, <string-name><surname>Damschroder</surname><given-names>MM.</given-names></string-name></person-group><article-title>Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody</article-title>. <source>MAbs</source><year>2015</year>;<volume>7</volume>:<fpage>428</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">25606664</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Furie</surname><given-names>RA</given-names></string-name>, <string-name><surname>Morand</surname><given-names>EF</given-names></string-name>, <string-name><surname>Bruce</surname><given-names>IN</given-names></string-name></person-group><etal>et al</etal><article-title>Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial</article-title>. <source>Lancet Rheumatol</source><year>2019</year>;<volume>1</volume>:<fpage>e208</fpage>–<lpage>19</lpage>.</mixed-citation>
              </ref>
              <ref id="keac491-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morand</surname><given-names>EF</given-names></string-name>, <string-name><surname>Furie</surname><given-names>R</given-names></string-name>, <string-name><surname>Tanaka</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal>; <collab>TULIP-2 Trial Investigators</collab>. <article-title>Trial of anifrolumab in active systemic lupus erythematosus</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>382</volume>:<fpage>211</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">31851795</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hochberg</surname><given-names>MC.</given-names></string-name></person-group><article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source><year>1997</year>;<volume>40</volume>:<fpage>1725</fpage>.</mixed-citation>
              </ref>
              <ref id="keac491-B15">
                <label>15</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Maruish</surname><given-names>ME.</given-names></string-name></person-group><source>User’s manual for the SF-36v2 health survey</source>. <edition>3rd edn.</edition><publisher-loc>Lincoln, RI</publisher-loc>: <publisher-name>QualityMetric Incorporated</publisher-name>, <year>2011</year>.</mixed-citation>
              </ref>
              <ref id="keac491-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lai</surname><given-names>JS</given-names></string-name>, <string-name><surname>Beaumont</surname><given-names>JL</given-names></string-name>, <string-name><surname>Ogale</surname><given-names>S</given-names></string-name>, <string-name><surname>Brunetta</surname><given-names>P</given-names></string-name>, <string-name><surname>Cella</surname><given-names>D.</given-names></string-name></person-group><article-title>Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial</article-title>. <source>J Rheumatol</source><year>2011</year>;<volume>38</volume>:<fpage>672</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">21239746</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Vollenhoven</surname><given-names>RF</given-names></string-name>, <string-name><surname>Mosca</surname><given-names>M</given-names></string-name>, <string-name><surname>Bertsias</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Treat-to-target in systemic lupus erythematosus: recommendations from an international task force</article-title>. <source>Ann Rheum Dis</source><year>2014</year>;<volume>73</volume>:<fpage>958</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">24739325</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doria</surname><given-names>A</given-names></string-name>, <string-name><surname>Gatto</surname><given-names>M</given-names></string-name>, <string-name><surname>Iaccarino</surname><given-names>L</given-names></string-name>, <string-name><surname>Punzi</surname><given-names>L.</given-names></string-name></person-group><article-title>Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight</article-title>. <source>Lupus</source><year>2015</year>;<volume>24</volume>:<fpage>507</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">25801894</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murimi-Worstell</surname><given-names>IB</given-names></string-name>, <string-name><surname>Lin</surname><given-names>DH</given-names></string-name>, <string-name><surname>Nab</surname><given-names>H</given-names></string-name></person-group><etal>et al</etal><article-title>Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis</article-title>. <source>BMJ Open</source><year>2020</year>;<volume>10</volume>:<fpage>e031850</fpage>.</mixed-citation>
              </ref>
              <ref id="keac491-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al Sawah</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>B</given-names></string-name></person-group><etal>et al</etal><article-title>Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort</article-title>. <source>Lupus Sci Med</source><year>2015</year>;<volume>2</volume>:<fpage>e000066</fpage>.<pub-id pub-id-type="pmid">25861455</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Casey</surname><given-names>KA</given-names></string-name>, <string-name><surname>Smith</surname><given-names>MA</given-names></string-name>, <string-name><surname>Sinibaldi</surname><given-names>D</given-names></string-name></person-group><etal>et al</etal><article-title>Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus</article-title>. <source>Arthritis Rheumatol</source><year>2021</year>;<volume>73</volume>:<fpage>459</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">32909675</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yazdany</surname><given-names>J</given-names></string-name>, <string-name><surname>Pooley</surname><given-names>N</given-names></string-name>, <string-name><surname>Langham</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis</article-title>. <source>RMD Open</source><year>2020</year>;<volume>6</volume>:<fpage>e001247</fpage>.<pub-id pub-id-type="pmid">32900883</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karp</surname><given-names>I</given-names></string-name>, <string-name><surname>Abrahamowicz</surname><given-names>M</given-names></string-name>, <string-name><surname>Fortin</surname><given-names>PR</given-names></string-name></person-group><etal>et al</etal><article-title>Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?</article-title><source>Arthritis Rheum</source><year>2008</year>;<volume>59</volume>:<fpage>169</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">18240259</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bruce</surname><given-names>IN</given-names></string-name>, <string-name><surname>Urowitz</surname><given-names>MB</given-names></string-name>, <string-name><surname>Gladman</surname><given-names>DD</given-names></string-name>, <string-name><surname>Hallett</surname><given-names>DC.</given-names></string-name></person-group><article-title>Natural history of hypercholesterolemia in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source><year>1999</year>;<volume>26</volume>:<fpage>2137</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">10529129</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leong</surname><given-names>KH</given-names></string-name>, <string-name><surname>Koh</surname><given-names>ET</given-names></string-name>, <string-name><surname>Feng</surname><given-names>PH</given-names></string-name>, <string-name><surname>Boey</surname><given-names>ML.</given-names></string-name></person-group><article-title>Lipid profiles in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source><year>1994</year>;<volume>21</volume>:<fpage>1264</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">7966068</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roman</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Shanker</surname><given-names>BA</given-names></string-name>, <string-name><surname>Davis</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus</article-title>. <source>N Engl J Med</source><year>2003</year>;<volume>349</volume>:<fpage>2399</fpage>–<lpage>406</lpage>.<pub-id pub-id-type="pmid">14681505</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>J</given-names></string-name>, <string-name><surname>Hebert</surname><given-names>PR</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>JO</given-names></string-name>, <string-name><surname>Hennekens</surname><given-names>CH.</given-names></string-name></person-group><article-title>Implications of small reductions in diastolic blood pressure for primary prevention</article-title>. <source>Arch Intern Med</source><year>1995</year>;<volume>155</volume>:<fpage>701</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">7695458</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hardy</surname><given-names>ST</given-names></string-name>, <string-name><surname>Loehr</surname><given-names>LR</given-names></string-name>, <string-name><surname>Butler</surname><given-names>KR</given-names></string-name></person-group><etal>et al</etal><article-title>Reducing the blood pressure-related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control</article-title>. <source>J Am Heart Assoc</source><year>2015</year>;<volume>4</volume>:<fpage>e002276</fpage>.<pub-id pub-id-type="pmid">26508742</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><collab>Blood Pressure Lowering Treatment Trialists Collaboration</collab>. <article-title>Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>:<fpage>1625</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">33933205</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berthon</surname><given-names>BS</given-names></string-name>, <string-name><surname>MacDonald-Wicks</surname><given-names>LK</given-names></string-name>, <string-name><surname>Wood</surname><given-names>LG.</given-names></string-name></person-group><article-title>A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans</article-title>. <source>Nutr Res</source><year>2014</year>;<volume>34</volume>:<fpage>179</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">24655484</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peckett</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Wright</surname><given-names>DC</given-names></string-name>, <string-name><surname>Riddell</surname><given-names>MC.</given-names></string-name></person-group><article-title>The effects of glucocorticoids on adipose tissue lipid metabolism</article-title>. <source>Metabolism</source><year>2011</year>;<volume>60</volume>:<fpage>1500</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">21864867</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Apostolopoulos</surname><given-names>D</given-names></string-name>, <string-name><surname>Vincent</surname><given-names>F</given-names></string-name>, <string-name><surname>Hoi</surname><given-names>A</given-names></string-name>, <string-name><surname>Morand</surname><given-names>E.</given-names></string-name></person-group><article-title>Associations of metabolic syndrome in SLE</article-title>. <source>Lupus Sci Med</source><year>2020</year>;<volume>7</volume>:<fpage>e000436</fpage>.<pub-id pub-id-type="pmid">33188034</pub-id></mixed-citation>
              </ref>
              <ref id="keac491-B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Northcott</surname><given-names>MN</given-names></string-name>, <string-name><surname>Gearing</surname><given-names>LN</given-names></string-name>, <string-name><surname>Nim</surname><given-names>HT</given-names></string-name></person-group><etal>et al</etal><article-title>Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study</article-title>. <source>Lancet Rheumatol</source><year>2021</year>;<volume>3</volume>:<fpage>e357</fpage>–<lpage>70</lpage>.</mixed-citation>
              </ref>
              <ref id="keac491-B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Strand</surname><given-names>V</given-names></string-name>, <string-name><surname>O’Quinn</surname><given-names>S</given-names></string-name>, <string-name><surname>Furie</surname><given-names>RA</given-names></string-name></person-group><etal>et al</etal><article-title>Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab</article-title>. <source>Lancet Rheumatol</source><year>2022</year>;<volume>4</volume>:<fpage>e198</fpage>–<lpage>207</lpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
